Titre : Dégradation des ARNm non-sens

Dégradation des ARNm non-sens : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neuroectodermal Tumors, Primitive
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dégradation des ARNm non-sens : Questions médicales les plus fréquentes", "headline": "Dégradation des ARNm non-sens : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dégradation des ARNm non-sens : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dégradation des ARNm non-sens" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maturation post-transcriptionnelle des ARN", "url": "https://questionsmedicales.fr/mesh/D012323", "about": { "@type": "MedicalCondition", "name": "Maturation post-transcriptionnelle des ARN", "code": { "@type": "MedicalCode", "code": "D012323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.308.700" } } }, "about": { "@type": "MedicalCondition", "name": "Dégradation des ARNm non-sens", "alternateName": "Nonsense Mediated mRNA Decay", "code": { "@type": "MedicalCode", "code": "D059365", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Lynne E Maquat", "url": "https://questionsmedicales.fr/author/Lynne%20E%20Maquat", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA." } }, { "@type": "Person", "name": "Luísa Romão", "url": "https://questionsmedicales.fr/author/Lu%C3%ADsa%20Rom%C3%A3o", "affiliation": { "@type": "Organization", "name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal. luisa.romao@insa.min-saude.pt." } }, { "@type": "Person", "name": "Fabrice Lejeune", "url": "https://questionsmedicales.fr/author/Fabrice%20Lejeune", "affiliation": { "@type": "Organization", "name": "Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France." } }, { "@type": "Person", "name": "Paulo J da Costa", "url": "https://questionsmedicales.fr/author/Paulo%20J%20da%20Costa", "affiliation": { "@type": "Organization", "name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal." } }, { "@type": "Person", "name": "Tatsuaki Kurosaki", "url": "https://questionsmedicales.fr/author/Tatsuaki%20Kurosaki", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Melanotic Neuroectodermal Tumor of Infancy: A Rare Case Report.", "datePublished": "2022-06-28", "url": "https://questionsmedicales.fr/article/35873838", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1750299" } }, { "@type": "ScholarlyArticle", "name": "Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?", "datePublished": "2023-10-16", "url": "https://questionsmedicales.fr/article/37908747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2023.1248575" } }, { "@type": "ScholarlyArticle", "name": "The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States.", "datePublished": "2022-12-15", "url": "https://questionsmedicales.fr/article/36522587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40618-022-01985-2" } }, { "@type": "ScholarlyArticle", "name": "Characteristics of small pancreatic neuroendocrine tumors and risk factors for invasion and metastasis.", "datePublished": "2023-03-20", "url": "https://questionsmedicales.fr/article/37020595", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2023.1140873" } }, { "@type": "ScholarlyArticle", "name": "Resection Versus Observation for Small (≤2 cm) Pancreatic Neuroendocrine Tumors.", "datePublished": "2022-09-22", "url": "https://questionsmedicales.fr/article/36134675", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/00031348221129501" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Régulation de l'expression des gènes", "item": "https://questionsmedicales.fr/mesh/D005786" }, { "@type": "ListItem", "position": 4, "name": "Maturation post-transcriptionnelle des ARN", "item": "https://questionsmedicales.fr/mesh/D012323" }, { "@type": "ListItem", "position": 5, "name": "Dégradation des ARNm non-sens", "item": "https://questionsmedicales.fr/mesh/D059365" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dégradation des ARNm non-sens - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dégradation des ARNm non-sens", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dégradation des ARNm non-sens", "description": "Comment diagnostiquer la dégradation des ARNm non-sens ?\nQuels tests sont utilisés pour évaluer la dégradation des ARNm ?\nQuels marqueurs biologiques indiquent une dégradation non-sens ?\nPeut-on détecter la dégradation des ARNm par imagerie ?\nQuel rôle joue la bioinformatique dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dégradation des ARNm non-sens", "description": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?\nLa dégradation des ARNm peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dégradation des ARNm non-sens", "description": "Peut-on prévenir la dégradation des ARNm non-sens ?\nY a-t-il des mesures préventives recommandées ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nLa sensibilisation est-elle importante pour la prévention ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dégradation des ARNm non-sens", "description": "Quels traitements existent pour la dégradation des ARNm non-sens ?\nLes thérapies géniques sont-elles efficaces ?\nY a-t-il des médicaments spécifiques pour cette condition ?\nLes traitements sont-ils personnalisés ?\nQuels sont les effets secondaires des traitements ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dégradation des ARNm non-sens", "description": "Quelles complications peuvent survenir ?\nLa dégradation des ARNm peut-elle entraîner des cancers ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dégradation des ARNm non-sens", "description": "Quels sont les facteurs de risque associés ?\nL'environnement influence-t-il la dégradation des ARNm ?\nLes infections peuvent-elles aggraver la dégradation des ARNm ?\nLe mode de vie a-t-il un impact sur les risques ?\nLes facteurs génétiques sont-ils déterminants ?", "url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Neuroectodermal+Tumors,+Primitive&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la dégradation des ARNm non-sens ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et l'analyse des ARNm par RT-PCR." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la dégradation des ARNm ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme le Northern blot et la séquençage d'ARN sont couramment utilisées." } }, { "@type": "Question", "name": "Quels marqueurs biologiques indiquent une dégradation non-sens ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'augmentation des ARNm contenant des mutations non-sens est un indicateur clé." } }, { "@type": "Question", "name": "Peut-on détecter la dégradation des ARNm par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'imagerie ne permet pas de détecter directement la dégradation des ARNm." } }, { "@type": "Question", "name": "Quel rôle joue la bioinformatique dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La bioinformatique aide à analyser les séquences d'ARN et à identifier les mutations non-sens." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon la maladie sous-jacente, incluant fatigue et troubles neurologiques." } }, { "@type": "Question", "name": "La dégradation des ARNm peut-elle causer des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs peuvent survenir en raison de maladies génétiques associées." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez les signes de dysfonctionnement organique ou neurologique." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains individus peuvent être asymptomatiques malgré la dégradation des ARNm." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver avec le temps, selon la gravité de la condition sous-jacente." } }, { "@type": "Question", "name": "Peut-on prévenir la dégradation des ARNm non-sens ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives recommandées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques peuvent être utiles pour les familles à risque." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des maladies ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent d'identifier les porteurs de mutations et de prendre des mesures." } }, { "@type": "Question", "name": "La sensibilisation est-elle importante pour la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la sensibilisation aux maladies génétiques peut aider à un diagnostic précoce." } }, { "@type": "Question", "name": "Quels traitements existent pour la dégradation des ARNm non-sens ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies géniques et des médicaments ciblant les ARNm." } }, { "@type": "Question", "name": "Les thérapies géniques sont-elles efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elles montrent des résultats prometteurs, mais leur efficacité dépend de la maladie." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques pour cette condition ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les modulateurs d'ARN peuvent être utilisés pour cibler les ARNm." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires varient, incluant des réactions allergiques et des troubles digestifs." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques et des maladies dégénératives." } }, { "@type": "Question", "name": "La dégradation des ARNm peut-elle entraîner des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations peuvent augmenter le risque de cancers, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications chroniques peuvent affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Comment les complications sont-elles traitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement des complications dépend de leur nature et peut inclure des thérapies ciblées." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque associés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux de maladies génétiques et des mutations spécifiques." } }, { "@type": "Question", "name": "L'environnement influence-t-il la dégradation des ARNm ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs environnementaux peuvent interagir avec des prédispositions génétiques." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver la dégradation des ARNm ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent exacerber les symptômes liés à la dégradation des ARNm." } }, { "@type": "Question", "name": "Le mode de vie a-t-il un impact sur les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire certains risques, mais ne prévient pas toutes les maladies." } }, { "@type": "Question", "name": "Les facteurs génétiques sont-ils déterminants ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations génétiques jouent un rôle clé dans la dégradation des ARNm non-sens." } } ] } ] }

Sources (10000 au total)

Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?

Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrine tumors (pNETs) has focused on genetic and epigenetic modifications and r... We retrieved and downloaded gene expression profiles from all publicly available gene set enrichments (GSE43797, GSE73338, and GSE117851) to compare the differences in expressed genes based on both th... By combining transcriptomic and metabolomic approaches, we have identified a distinctive metabolism in pNETs compared with controls without pNETs. Our analysis showed dysregulations in the one-carbon,...

The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States.

The incidence of pancreatic neuroendocrine tumors (pNETs) was increasing. The main purpose of this study was to statistically analyze the incidence and prevalence of pNETs and the main risk factors fo... Based on the Surveillance, Epidemiology, and End Results (SEER) database, with three registries integrated, this study comprehensively displayed the annual age adjust incidence of pNETs from 1975 to 2... The incidence of pNETs has increased to about 1.5 per 100,000 population, and the prevalence has reached about 0.008% with the aged, Grade 1 and nonfunctional tumors accounting for the majority. The a... The incidence and prevalence of pNETs were still increasing, but the trend was gradual and aging in recent years. The survival time of pNETs was longer but has not changed much in recent years. The de...

Characteristics of small pancreatic neuroendocrine tumors and risk factors for invasion and metastasis.

The number of people with small pancreatic neuroendocrine tumors (pNETs) (tumors with a diameter less than or equal to 2 cm) is gradually increasing, but the selection of treatment strategy is still c... Patients with pNETs diagnosed between 2004 and 2019 and a tumor diameter of 2 cm or less were selected from the SEER Registry. Kaplan-Meier survival analysis was used to identify the factors affecting... A total of 3261 patients with pNETs were enrolled in the study. Both older and younger patients benefited from surgery. Regional invasion occurred in 10% of the patients, and distant metastases occurr... The pNETs ≤ 2 cm in diameter could be still aggressive, and patient prognosis worsens after invasive disease develops. Attention to the characteristics of aggressive tumors can improve patient surviva...

Resection Versus Observation for Small (≤2 cm) Pancreatic Neuroendocrine Tumors.

We hypothesized that those patients with pancreatic neuroendocrine tumors (pNETs) ≤2 cm managed nonoperatively would have comparable disease progression to individuals undergoing an operation.... Patients diagnosed with nonfunctional pNETs ≤ 2 cm who were evaluated at a single comprehensive cancer center from 2010 to 2017 were selected from a cancer registry database. Clinicopathologic variabl... Fifty-two individuals had tumors ≤2 cm, of whom 75% had an operation, while 25% were observed. Each treatment arm had similar distributions of gender, race, and tumor location. The most common operati... Overall disease progression in patients with pNETs ≤ 2 cm without evidence of metastasis at the time of presentation is not different between those who underwent operation compared to those observed....

Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.

Surgery is the only known cure for sporadic pancreatic neuroendocrine tumors (PNETs). Therefore, the prediction of the PNETs biological aggressiveness evaluated on endoscopic ultrasound-guided fine-ne... A retrospective observational study was performed on patients undergoing surveillance for PNETs from January 2010 to May 2021. Data collection included the patients' age, sex, tumor location, tumor si... After excluding cell blocks containing fewer than 100 tumor cells, 44 patients with EUS-FNA and surgical resection specimens were included in this study. There were 19 cases of G1 PNETs, 20 cases of G... Grade and the proliferative rate in EUS-FNA can be used to predict the tumor grade in surgical resection specimens. However, when using only FNA Ki-67 to predict PNET tumor grade, about 18 % of cases ...

Embryonal tumor with multilayered rosettes: Post-treatment maturation and implications for future therapy.

Embryonal tumor with multilayered rosettes (ETMR) is a deadly grade IV pediatric brain tumor. Despite an intensive multimodal treatment approach that includes surgical resection, high-dose chemotherap... We report a case of long-term survival in a 5-month old female with a large mass in the posterior fossa, diagnosed as ETMR, which subsequently underwent treatment-induced maturation. Prior to chemothe... This finding contributes to the few reports to date of post-treatment differentiation/maturation of ETMR cell populations, with an implication for less cytotoxic therapeutic interventions aimed at dif...

Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors.

Approximately 40-50% of patients with pancreatic neuroendocrine tumors (pNETs) initially present with distant metastases. Little is known about the outcomes of patients undergoing combined pancreatic ... Patients who underwent hepatectomy for metastatic pNETs at Mayo Clinic Rochester from 2000 to 2020 were retrospectively reviewed. Major pancreatectomy was defined as pancreaticoduodenectomy or total p... 205 patients who underwent hepatectomy for metastatic pNETs were identified: 131 underwent pancreatectomy with simultaneous hepatectomy and 74 underwent isolated hepatectomy. Among patients undergoing... For patients with metastatic pNETs, combined pancreatic and hepatic resections can be performed with acceptable morbidity and mortality in selected patients at high-volume institutions....

Bone mineral density and nutrition in long-term survivors of childhood brain tumors.

Childhood cancer survivors are at risk of unwanted late effects. The primary aim of this study was to assess bone mineral density Z-scores (BMDz) in long-term survivors of childhood medulloblastoma (M... All MB and CNS-PNET survivors treated at Oslo University Hospital from 1974 to 2013 were invited to participate in a cross-sectional study. Dual-energy x-ray absorptiometry (Lunar Prodigy) assessed BM... Fifty survivors with a median age of 25.5 years (5.5-51.9) and a median follow-up time of 19.5 years (3.2-40.5) were included. Mean BMDz lumbar spine was -0.8 (SD 1.1, 95% CI: -1.1 to -0.4), and BMDz ... Long-term survivors of childhood MB and CNS-PNET had decreased BMDz, and risk factors were male sex, higher age at diagnosis, and lower LMI. Inadequate calcium and vitamin D intake, an inactive lifest...